rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi.
|
12447372 |
2003 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi.
|
12447372 |
2003 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation.
|
14522889 |
2003 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation.
|
14522889 |
2003 |
rs121913227
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma.
|
14522889 |
2003 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of B-raf exon 15 mutations or prediction of the activating mutation V599E were not statistically associated with the risk for subsequent metastasis in the follow-up of patients.
|
15331929 |
2004 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of B-raf exon 15 mutations or prediction of the activating mutation V599E were not statistically associated with the risk for subsequent metastasis in the follow-up of patients.
|
15331929 |
2004 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Sixty-eight samples (20 of 36 primaries, 18 of 27 regional metastases, 16 of 40 nodal metastases, and 9 of 12 distant metastases) harbored the V599E B-RAF mutation (59%), 17 contained a Q61R N-RAS mutation, and 4 contained a Q61K N-RAS mutation.
|
15737846 |
2005 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Sixty-eight samples (20 of 36 primaries, 18 of 27 regional metastases, 16 of 40 nodal metastases, and 9 of 12 distant metastases) harbored the V599E B-RAF mutation (59%), 17 contained a Q61R N-RAS mutation, and 4 contained a Q61K N-RAS mutation.
|
15737846 |
2005 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unexpectedly, V599 and V599E mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as preceding primary tumours.
|
15935100 |
2005 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unexpectedly, V599 and V599E mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as preceding primary tumours.
|
15935100 |
2005 |
rs121913227
|
|
|
0.080 |
GeneticVariation |
BEFREE |
As to the B-raf protein sequence, the acidic amino acid transitions V599E and V599K were predicted in 19/60 (32%) and 6/60 (10%) cases, respectively, but were not associated with enhanced risk for subsequent metastasis in patients' follow up.
|
15935100 |
2005 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF V599E mutations.
|
16098043 |
2005 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF V599E mutations.
|
16098043 |
2005 |
rs121913227
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The oncogenic B-raf mutations V599E and V599K, as early events in melanocyte transformation, persist throughout metastasis with important prognostic implications.
|
16179870 |
2005 |
rs121913364
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Further studies are necessary to clarify the putative clinical significance (e.g. association to blood-born metastases) of PAX8-PPARgamma rearrangement, RAS mutations, and BRAF(K601E) in FVPTCs.
|
16219715 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) significantly correlated with absence of node metastasis.
|
16452550 |
2006 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) significantly correlated with absence of node metastasis.
|
16452550 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, this study provides a mechanistic basis for targeting Mek and not B-Raf in the mutant (V600E)B-Raf signaling cascade to inhibit melanoma metastases.
|
16912199 |
2006 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, this study provides a mechanistic basis for targeting Mek and not B-Raf in the mutant (V600E)B-Raf signaling cascade to inhibit melanoma metastases.
|
16912199 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is identified in a subset of cutaneous metastases from PTC.
|
17387744 |
2007 |